Beam Q2 net loss $82.8M; BEAM-101/201 trials advance, in vivo programs accelerated

Beam Therapeutics Inc.

2023-Q2 EPS reported -$2.41 revenue$44,324,000

Q2 net loss $82.8M ($1.08/shr) vs $72.0M ($1.02/shr) in Q2 2022; R&D spend $97.6M (up 31% YoY).
Cash $1.1B unchanged from year-end 2022; runway extends at least into 2025.
BEACON trial: consented patients sufficient to fill sentinel and initiate expansion; initial data expected 2024.
BEAM-201: first patient consented, dosing expected Q3 2023; multiple clinical sites open.
BEAM-302 accelerated to first in vivo liver regulatory filing in Q1 2024; BEAM-301 filing in H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Beam Therapeutics Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 8, 2023, Beam Therapeutics Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039356

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.